[Federal Register Volume 68, Number 75 (Friday, April 18, 2003)]
[Notices]
[Pages 19214-19215]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-9546]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Use of Hydroxyurea Alone 
and in Combination with dNTP Competitors for Blocking Reverse 
Transcriptase Dependent Viruses

AGENCY: National Institutes of Health, Public Health Service, HHS.

[[Page 19215]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the invention embodied in:
    (1) U.S. Patent No. 6,194,390, issued Feb. 27, 2001, entitled 
``Procedure to block the replication of reverse transcriptase dependent 
viruses by the use of inhibitors of deoxynucleotides synthesis'' (E-
157-1993/7);
    (2) U.S. Patent No. 6,046,175, issued April 4, 2000, entitled 
``Procedure to block the replication of reverse transcriptase dependent 
viruses by the use of inhibitors of deoxynucleotides synthesis'' (E-
157-1993/1);
    (3) U.S. Patent No. 6,093,702, issued July 25, 2000, entitled 
``Mixtures of dideoxynucleosides and hydroxycarbamide for inhibiting 
retroviral spread'' (E-157-1993/4);
    (4) U.S. Patent No. 5,736,526, issued April 7, 1998, entitled 
``Mixtures of DDI and D4T with hydroxycarbamide for inhibiting 
retroviral replication'' (E-157-1993/5);
    (5) U.S. Patent No. 5,521,161, issued May 28, 1996, entitled 
``Method of treating HIV in humans by administration of ddI and 
hydroxycarbamide'' (E-157-1993/2);
    (6) U.S. Patent No. 5,736,527, issued April 08, 1998, entitled 
``Method of treating HIV in humans by administration of ddI and 
hydroxycarbamide'' (E-157-1993/6);
    (7) PCT/US94/05515 filed May 17, 1994, entitled ``Procedure to 
block the replication of reverse transcriptase dependent viruses by the 
use of inhibitors of deoxynucleotides synthesis'' (E-157-1993/1), 
National Stage filed May 17, 1994: in Canada application No. 2163456, 
in EPO application No. 94918016.0, in Japan application No. 518466/94, 
in Australia Patent No. 685128, issued April 30, 1998;
    (8) PCT/US95/00153 filed Dec. 20, 1994, entitled ``Method of 
treating HIV in humans by administration of ddI and hydroxycarbamide'' 
(E-157-1993/2), National Stage filed Dec. 20, 1994: in Canada Patent 
No. 2179627, issued Feb. 22, 2000, in EPO Patent No. 0735890, issued 
April 17, 2002, in South Africa Patent No. 94/9219, issued Oct. 25, 
1995, in Taiwan Patent No. NI-080011, issued Dec. 03, 1996, in 
Australia Patent No. 718325, issued July 27, 2000, OAIPO Patent 
Application No. 60849, in Brazil patent application No. PI1100041-4, in 
Mexico patent application No. 9409706 to Research Institute for Genetic 
and Human Therapy (RIGHT), having a place of business in Washington, 
DC. The patent rights in these inventions have been assigned to the 
United States of America.

DATES: Only written comments and/or application for a license, which 
are received by the NIH Office of Technology Transfer on or before June 
17, 2003 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Sally Hu, Ph.D., M.B.A., Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; E-mail: [email protected]; Telephone: 
(301) 435-5606; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless, within 60 days from the date of this published Notice, 
NIH receives written evidence and argument that establishes that the 
grant of the license would not be consistent with the requirements of 
35 U.S.C. 209 and 37 CFR 404.7.
    The subject inventions provide for formulations and methods for 
inhibiting replication of reverse transcription dependent viruses in 
animals cells comprising administering a compound that depletes the 
intracellular pool of deoxyribonucleoside phosphate (e.g. hydroxyurea), 
and further comprising administering a compound that serves to inhibit 
replication of the virus by terminating DNA chain elongation (e.g. 
DDI).
    The field of use may be limited to development of drugs of 
hydroxyurea alone and in combination with dNTP competitors for blocking 
reverse transcriptase dependent viruses, including HIV.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 10, 2003.
Steven M. Ferguson,
Acting Director, Division of Technology Development and Transfer, 
Office of Technology Transfer.
[FR Doc. 03-9546 Filed 4-17-03; 8:45 am]
BILLING CODE 4140-01-P